1. P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES. (23rd June 2022) Authors: Grandclement, C.; Estoppey, C.; Dheilly, E.; Panagopoulou, M.; Martini, E.; Labanca, V.; De Angelis, S.; Frei, J.; Drake, A.; Rubod, A.; Gudi, G.; Udupa, V.; Koch Olsen, J.; Giovannini, R.; Doucey, M. A.; Feldman, E.; Konto, C.; Srivastava, A.; Perro, M.; Sammicheli, S. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 764 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗